title: Rapid onset of control with budesonide Turbuhaler in patients with mild-to-moderate asthma.
abstract: BACKGROUND
  Budesonide (Pulmicort) is an inhaled corticosteroid with high topical potency but low systemic activity. Turbuhaler is a novel breath-actuated, multi-dose, dry-powder inhaler.
  
  
  OBJECTIVE
  This study was conducted to determine the efficacy and safety of two different dose regimens of budesonide Turbuhaler, compared with placebo, in adult patients with mild-to-moderate asthma not well-controlled with bronchodilator therapy.
  
  
  METHODS
  This double-blind, randomized, placebo-controlled, parallel-group, multicenter study compared the efficacy and safety of 200 microg and 400 microg of budesonide, administered twice daily via Turbuhaler, with placebo, in 273 adult patients (aged 19 to 70 years) with mild-to-moderate asthma (FEV1 67% of predicted normal), not well-controlled with bronchodilator therapy. Efficacy was assessed by pulmonary function tests and patient assessments of asthma symptom control. Safety was assessed in terms of adverse events, laboratory evaluations, and physical examinations.
  
  
  RESULTS
  Two hundred and 400 microg of budesonide bid were significantly more effective than placebo at improving morning PEF (mean differences from placebo of 43.63 L/min and 40.10 L/min, respectively; P < .001) and FEV1 (mean differences from placebo of 0.44 L, and 0.50 L, respectively; P < .001) over the 12-week treatment period. Onset of action as assessed by morning PEF was within two days. Basal and stimulated plasma cortisol concentrations were not significantly affected by budesonide treatment compared with placebo.
  
  
  CONCLUSIONS
  Treatment of adults suffering from mild-to-moderate asthma with budesonide Turbuhaler is well tolerated and results in a rapid onset of asthma control which is maintained over time.
authors.affiliation: Clinical Trials Center, La Jolla, California, USA.
authors.forename: J
authors.initials: J
authors.lastname: Kemp
authors.forename: A A
authors.initials: AA
authors.lastname: Wanderer
authors.forename: J
authors.initials: J
authors.lastname: Ramsdell
authors.forename: D L
authors.initials: DL
authors.lastname: Southern
authors.forename: S
authors.initials: S
authors.lastname: Weiss
authors.forename: D
authors.initials: D
authors.lastname: Aaronson
authors.forename: J
authors.initials: J
authors.lastname: Grossman
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D001249:Asthma / Q000517:prevention & control*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019819:Budesonide / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012720:Severity of Illness Index; D013810:Therapeutic Equivalency
chemical_list: D001993:Bronchodilator Agents; D010919:Placebos; D019819:Budesonide; D006854:Hydrocortisone